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Abstract
Background: Several medications for treatment of Juvenile Idiopathic Arthritis (JIA) are considered to be carcinogenic.
Therefore, the aim was to assess whether there is an association between therapeutic interventions and malignancies
in JIA patients.
Findings: A nested case–control study was carried out within a retrospective cohort study of 3698 JIA
patients diagnosed between 1952 and 2010. All 48 JIA patients with a diagnosis of a malignant tumour and
up to four matched controls for each received a questionnaire about their use of medication. Subsequently
treatment was compared between cases and controls and analyses performed for 37 cases and 125 controls
(response 88.5 %). Treatment with DMARD (84 %) was most frequently used, followed by glucocorticoids
(66 %) and immunosuppressives (65 %). Twenty percent reported to have ever been taking biologics.
Medication use did not differ significantly between cases and controls.
Conclusions: Our results did not show an association between medications used and malignancies in JIA patients.




Patients with Juvenile Idiopathic Arthritis (JIA) are con-
sidered to be at higher risk of malignancies than the
general population [1]. Potential explanations for this in-
creased risk might be the inflammatory process under-
lying the disease [2], frequent use of diagnostic
procedures involving exposure to ionizing radiation [3]
or therapeutic interventions [1].
Over the last two decades, new therapeutic options
seem to have considerably improved treatment and out-
come [4–7]. Substantial therapeutic improvement was
achieved through the introduction of biologic agents [4]
such as Tumour-necrosis-factor-alpha (TNFα)-blockers
for example [4, 8]. However, concerns about these medi-
cations were first risen in 2008 by the Food and Drug
Administration (FDA) resulting in a warning about a
possible association between the use of TNFα-blockers
and the development of malignancies in children and
young adults [9]. However, since subsequent studies
could not confirm such an association for patients with
JIA treated with TNFα-blockers, it has been suggested
that the association between TNFα-blockers and malig-
nancy might be confounded by the concomitant intake
of immunosuppressive agents [10] or by the inflamma-
tory process itself [2, 11].
Most recently published reviews on the subject matter
concluded that an association between use of biologics
and malignancies is unlikely, but that more long-term
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studies are needed to be able to draw definite conclusions
[1, 4, 12]. Therefore, this study carried out a retrospective
cohort study on cancer incidence in 3692 JIA patients
(Barth S, Schlichtiger J, Hartmann B, Bisdorff B, Michels
H, Radon K et al. Incidence of malignancies in patients
with Juvenile Idiopathic Arthritis: a retrospective single-
centre cohort study,submitted.) Nested within this retro-
spective cohort study, a case–control study to investigate
whether type of treatment differed between JIA patients
with and without cancer was also performed.
Methods
Study design and study population
A nested case–control study was carried out within of a
retrospective single-centred hospital-based cohort study
of 3698 JIA patients. In 2012, all current and former JIA
patients that had been admitted to the German Centre for
Pediatric and Adolescent Rheumatology (GCPAR) in
Garmisch-Partenkirchen (Germany) between 1952 and
2010 (n = 10,580) were sent a self-administered standard-
ized questionnaire. Overall, 6127 completed the question-
naire and gave written informed consent. As described
elsewhere (Barth S, Schlichtiger J, Hartmann B, Bisdorff B,
Michels H, Radon K et al. Incidence of malignancies in pa-
tients with Juvenile Idiopathic Arthritis: a retrospective
single-centre cohort study,submitted), by means of
reviewing the actual medical records at the GCPAR, JIA
patients were identified and those suffering from other
(rheumatic) diseases excluded (Barth S, Schlichtiger J,
Hartmann B, Bisdorff B, Michels H, Radon K et al. Inci-
dence of malignancies in patients with Juvenile Idiopathic
Arthritis: a retrospective single-centre cohort study,sub-
mitted). Of the remaining participants, all patients reporting
a malignant tumour were defined as cases (International
Classification of Diseases, Ninth Revision (ICD9) 140–208).
Subsequently, a total of 48 cases were individually matched
by sex, age (+/− 2 years) and date of first admission to the
hospital (+/− 2 years) with up to four controls each. These
were selected out of the JIA cohort from the same study. In
the spring of 2013, all cases and 135 controls received a
second self-administered standardized questionnaire
including informed consent. The study was approved by
the medical ethics committee of the University Hospital
of Munich (LMU) in September 2011.
Questionnaire
A 19-item self-administered questionnaire (copy available
from the authors upon request) was used to assess:
– Comorbidities (diabetes, HIV, mononucleosis,
Crohn's disease, ulcerative colitis, multiple sclerosis,
Hashimoto's thyroiditis, and trisomy 21),
– Drug intake (abatacept, adalimumab, anakinra,
azathioprine, cyclophosphamide, chlorambucil,
chloroquine, cyclosporine a, D-penicillamine, etaner-
cept, hydroxychloroquine, infliximab, leflunomide,
methotrexate, mycophenolatmofetil, natriumaur-
othiomalate, oral cortisone, rituximab, sulfasalazine,
tocilizumab),
– If a specific type of drug was taken, duration of intake
was requested (<6 month, 6 month-2 years, >2 years),
– Potential other risk factors of cancer (parental
cancer history, computed tomography (CT), x-ray,
scintigraphy, nuclear radiation therapy).
In addition, sociodemographic data (age, sex, educa-
tion of participants and their parents) and disease-
related information (disease duration and age at first
symptoms of JIA) were taken from the cohort question-
naire that had previously been filled out (Barth S,
Schlichtiger J, Hartmann B, Bisdorff B, Michels H,
Radon K et al. Incidence of malignancies in patients with
Juvenile Idiopathic Arthritis: a retrospective single-
centre cohort study,submitted).
Data were double entered into SurveyMonkey (Survey-
Monkey Inc., USA) and the entries checked with
Synkronizer 10.0 (©2000–2014, XL Consulting GmbH,
Switzerland).
Variable definitions
The assessed drugs were categorized into following
active ingredient groups:
 disease-modifying antirheumatic drugs (DMARDs)
(chloroquine, hydroxychloroquine, sulfasalazine, D-
penicillamine, natriumaurothiomalate, methotrexate,
cyclosporine a, leflunomide, mycophenolatmofetil,
azathioprine)
 cytostatics (cyclophosphamide, chlorambucil)
 glucocorticoids (oral cortisone)
 immunosuppressives (methotrexate, cyclosporine a,
leflunomide, mycophenolatmofetil, azathioprine,
cyclophosphamide, chlorambucil)
 biologic agents (abatacept, anakinra, etanercept,
infliximab, rituximab, tocilizumab, adalimumab)
Statistical analyses
Absolute and relative frequencies were used to describe
categorical data. For continuous data, measures of cen-
tral tendency (median values) and measures of disper-
sion (1st–3rd quartile and range) were calculated. All
analyses were stratified for cases and controls. Differ-
ences between cases and controls were identified using
conditional (fixed-effect) logistic regression analyses;
Odds Ratios (OR) and 95 %-Confidence Intervals (95 %-
CI) were calculated. Due to the large numbers of missing
values for drug intake, sensitivity analyses were performed.
Multivariate analyses were repeated first including a
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missing category for the drug variables, followed by the
coding of the missing values as “drug was not taken”.
These results were compared then to the main analyses.
Furthermore, drug intake was validated by sending a sec-
ond questionnaire with the same questions on drug intake
out again about a year later. By calculating Cramer`s V
values we tested reliability of answers. All statistical ana-
lyses were performed using Stata software version 12.1
(StataCorp LP, USA).
Results
The study population consisted of 48 cases and 135 con-
trols with 37 cases and 125 controls responding (re-
sponse 88.5 %). Median age of participants was 43 years
(1st–3rd quartile: 33–50 years; range: 12–67 years), 82 %
were female and most participants had a medium (41 %)
or high (38 %) level of education (Table 1). The most
common type of cancer was melanoma (n = 9), followed
by breast cancer (n = 7) and cervical cancer (n = 5). All
other types of cancer occurred in three or fewer patients.
Median duration from onset of JIA to diagnosis of the
malignant tumour was 26 years (1st-3rd quartile: 21–
34.5; range: 9–47 years).
On average, cases and controls had exposure to
three different drugs during the course of their dis-
ease (range: 0–17). Intake of any antirheumatic medi-
cation during the last 12 months was reported by
49 % (data not shown). Treatments most frequently
included: oral cortisone (66 %), methotrexate (51 %),
natriumaurothiomalate (47 %) and chloroquine
(42 %). Steroids were taken by 39 % for more than
two years thus being the medication with the longest
duration of intake. Duration of intake and type of
drugs did not differ between cases and controls (see
Additional file 1).
Considering the categorized active ingredient groups,
treatment most commonly included DMARD (84 %).
More than half of all patients reported intake of






Total 37 (22.8) 125 (77.2)
Sex of the participant
Male 0 7 (18.9) 23 (18.4) n. a.
Female 30 (81.1) 102 (81.6)
Age (years)
0–17 0 2 (5.4) 8 (6.4) n. a.
18–24 0 (0.0) 0 (0.0)
25–34 7 (18.9) 28 (22.4)
35–44 12 (32.4) 39 (31.2)
45–54 10 (27.0) 36 (28.8)
55–76 6 (16.2) 14 (11.2)
Education of participantb
Low 3 8 (21.6) 25 (20.5) 1.00 (Ref.)
Medium 14 (37.8) 51 (41.8) 0.90 (0.33;2.46)
High 15 (40.5) 46 (37.7) 1.03 (0.35;3.06)
Parental education
Low 35 12 (44.4) 39 (39.0) 1.00 (Ref.)
Medium 9 (33.3) 35 (35.0) 0.85 (0.28;2.53)
High 6 (22.2) 26 (26.0) 1.18 (0.33;4.16)
Disease duration since first symptoms (years) 65
Median (1st–3rd quartile) (range) 41 (35;44) (3;57) 39 (34.5;45) (4;62) 0.97 (0.83;1.13)
Age at first symptoms (years) 65
Median (1st–3rd quartile) (range) 8.5 (5;11) (1;13) 8 (4;11) (0;15) 1.03 (0.90;1.19)
OR odds ratio, CI confidence interval, n. a not available, DMARD disease-modifying anti-rheumatic drugs, CT computed tomography
aOR of conditional (fixed-effects) logistic regression analysis with cancer (yes/no) as outcome. For each independent variable a separate model was created
bLevel of education was summarized into high (higher school certificate, university, or college degree), medium (secondary school leaving certificate, or
comparable degree) and low (lower secondary education level or no degree). For children, pupils and for those who did not indicate their level of education the
highest parental level of education was used as a proxy
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glucocorticoids (66 %) and immunosuppressives (65 %).
Biologics were ingested by 20 % of all respondents and
cytostatics by 6 %. The intake of the investigated drugs
was not statistically significant associated with being a
case (Table 2) – not even in sensitivity analyses when
the large number of missing values was considered (data
not shown).
With regard to other potential factors, an association
between exposure to scintigraphy and nuclear radiation
therapy could be shown. However, in this context it has
to be considered that both are used for the diagnosis of
cancer. Therefore, with our data it is not possible to
classify these as risk factors for cancer since application
took place or simultaneously or after diagnosis of cancer.
The remaining factors showed a tendency leading to
(family history of cancer, x-ray) or having no impact on
cancer (Table 3).
Validation of drug intake revealed moderate agreement
with most of Cramer´s V values between 0.52 and 0.74
except for two, which showed lower agreement (ana-
kinra: 0.29 and mycophenolatmofetil: 0.30).
Discussion
This study compared drug intake and exposure to differ-
ent already established cancer risk factors between JIA
patients with and without malignancies. No statistical
significant difference regarding drug intake was found.
Only two of the already previously established risk fac-
tors were confirmed (exposure to scintigraphy, nuclear
radiation therapy) in this study.
These results are in line with several previous studies
that either found no increased incidence of malignancies
in JIA patients [13–15] or an increased risk for cancer
independent of TNF-α-treatment [1, 16–20]. However,
some studies suggested that new therapeutics might be
responsible for an increased risk of cancer in JIA pa-
tients [13, 21]. On the contrary it has been suggested
that the use of biologic agents, among others, lowers the
background risk of JIA for malignancies in reducing the
inflammatory process of the disease [12].
Although, drug intake did not differ between cases and
controls we found differences with regards to use of scintig-
raphy and nuclear radiation therapy, which was more often
used in the cases. However, these results were to be expected
since these methods are used for cancer diagnosis [22, 23].
For some variables we had a high number of missing
values especially for date of first symptoms and drug in-
take; date of first symptoms was often unknown and is
generally hard to define.
The reliability of information based on response to the
questions on drug intake is a major limiting factor of
this study, as it was too difficult for some of the patients
to remember such detailed questions retrospectively. We
used several methods in order to control for possible
bias due to missing values. No statistically significant dif-
ferences were found between patients with and without
a missing value in one of the drug variables. Inclusion of
missing values into multivariate analyses revealed no ef-
fect on having cancer, number of missing values did not
differ between cases and controls.
Table 2 Participants drug intake





Total 37 (22.8) 125 (77.2)
DMARD
No 10 (6.17) 5 (14.3) 20 (17.1) 1.00 (Ref.)
Yes 30 (85.7) 97 (82.9) 1.25 (0.42;3.76)
Immunosuppressives
No 21 (12.96) 11 (35.5) 39 (35.5) 1.00 (Ref.)
Yes 20 (64.5) 71 (64.6) 0.97 (0.42;2.27)
Cytostatics
No 42 (25.93) 27 (93.1) 86 (94.5) 1.00 (Ref.)
Yes 2 (6.9) 5 (5.5) 1.29 (0.23;7.18)
Glucocorticoids
No 26 (16.05) 7 (21.2) 39 (37.9) 1.00 (Ref.)
Yes 26 (78.8) 64 (62.1) 2.31 (0.88;6.10)
Biologics
No 38 (23.46) 25 (86.2) 74 (77.9) 1.00 (Ref.)
Yes 4 (13.8) 21 (22.1) 0.75 (0.24;2.38)
OR odds ratio, CI confidence interval, DMARD disease-modifying anti-rheumatic drugs
aOR of conditional (fixed-effects) logistic regression analysis with cancer (yes/no) as outcome. For each independent variable a separate model was created
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On one hand the long recruitment period can be con-
sidered a strength of the study,but simultaneously it
might also have lead to a possible recall bias.
Especially, in the context of drug intake recall bias
cannot be excluded as the results of drug validation
showed only moderate agreement between first and sec-
ond drug questionnaire. Therefore, the results should be
interpreted with caution. Validation of drug intake with
medical records was anticipated, but in the end was not
possible as most patients are now being treated else-
where. Therefore, obtaining all medical records of the
patients was not feasible in the context of this study.
Lower the number of missing values was not success-
ful not even by phoning participants up; most frequently
they stated that they could not remember the name of
the drugs. Multiple medications were not considered as
a potential risk factor for cancer in this study but might
well be relevant for future studies. Another obvious re-
striction of the study was the small number of cases.
However, with regards to the total number of cases in
the first part of the study 90 % of all cases were reached
for the follow-up. Nevertheless, to draw valid conclu-
sions for the differences between cases and controls re-
garding drug treatment and other environmental cancer
risk factors larger case–control-studies are needed.
Therefore in this study it has to be considered that miss-
ing differences between cases and controls were due to
missing power.
In conclusion, this study on cancer cases from a large
single-centered population over a time period of more






Total 37 (22.8) 125 (77.2)
Parental cancer history
No 3 18 (51.4) 78 (62.9) 1.00 (Ref.)
Yes 17 (48.6) 46 (37.1) 1.94 (0.92;4.13)
Ever Smoked
No 1 16 (44.4) 66 (52.8) 1.00 (Ref.)
Yes 20 (55.6) 59 (47.2) 1.49 (0.66;3.41)
Currently smoking
No 0 29 (78.4) 94 (75.2) 1.00 (Ref.)
Yes 8 (21.6) 31 (24.8) 0.84 (0.32;2.15)
CT
No 0 9 (24.3) 60 (48.0) 1.00 (Ref.)
Yes 28 (75.7) 65 (52.0) 0.95 (0.51;1.76)
Scintigraphy
No 0 17 (45.9) 91 (72.8) 1.00 (Ref.)
Yes 20 (54.1) 34 (27.2) 2.01 (1.15;3.50)
X-ray (dentist)
0–5 20 16 (47.1) 46 (42.6) 1.0 (Ref.)
6–10 10 (29.4) 29 (26.9) 0.96 (0.37;2.48)
11–20 5 (14.7) 19 (17.6) 0.81 (0.25;2.69)
>20 3 (8.8) 14 (13.0) 0.65 (0.16;2.71)
X-ray
0–5 15 1 (2.8) 11 (9.9) 1.00 (Ref.)
6–10 2 (5.6) 14 (12.6) 1.85 (0.15;22.58)
11–20 10 (27.8) 29 (26.1) 4.27 (0.46;39.39)
>20 23 (63.9) 57 (51.4) 4.34 (0.52;36.01)
Nuclear radiation therapy
No 1 26 (70.3) 114 (91.9) 1.00 (Ref.)
Yes 11 (29.7) 10 (8.1) 3.04 (1.25;7.36)
OR odds ratio, CI confidence interval, aOR of conditional (fixed-effects) logistic regression analysis with cancer (yes/no) as outcome
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than half a century, could not suggest an increased risk
of malignancies in JIA patients associated with JIA
therapy.
Additional file
Additional file 1: Intake and duration of rheumatic drugs. (DOCX
28 kb)
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